Global DNA-Encoded Library Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global DNA-Encoded Library Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

DNA-encoded chemical libraries (DEL) is a technology for the synthesis and screening on an unprecedented scale of collections of small molecule compounds.

Market Overview:

The latest research study on the global DNA-Encoded Library market finds that the global DNA-Encoded Library market reached a value of USD 464.59 million in 2022. It’s expected that the market will achieve USD 1736.33 million by 2028, exhibiting a CAGR of 24.57% during the forecast period.

Global trade in intermediate goods accounts for more than half of global trade in goods, and global supply chains are closely integrated. China, the United States and Germany have become the industrial chain hub of East Asia, North America and Western Europe respectively. The epidemic has had an impact on the industrial chain, especially in industries such as electronic and mechanical equipment that are highly integrated in the global value chain. The COVID-19 outbreak has led to a slowdown in DNA-Encoded Library research activity, mainly in the form of raw material shortages, disruptions to the research and development workforce, and global logistics disruptions. But as countries around the world continue to face widespread damage from the COVID-19 pandemic, biotechnology is an important weapon in the fight against disease. Researchers are racing to find a diagnosis, a vaccine and a treatment. In this important scientific effort, research turned to the DNA-Encoded Library. This has greatly increased the demand for DNA-Encoded Library.

More advantages than traditional methods

DEL screens offer various benefits over conventional approaches like HTS for LMW compounds or phage display for peptide discovery, thereby enabling rapid access to both tool compounds as well as suitable starting points for drug discovery projects. First of all, the sizes of the respective input libraries are larger, allowing the chemical space to be more deeply sampled in just one screen. Additionally, in comparison to other display systems (like phage or yeast), less library focusing is inherent to these cell-free techniques, i.e., less reduction of the starting pools diversity due to different growth rates of the employed cellular systems.

Long development cycle

Biosimilars are thought to take eight to 10 years to develop, much longer than the three to five years for generic chemical drugs. Some estimates put the cost of a typical generic chemical drug at $2m-3m, and for biosimilars at $0.75m - $250m. Innovative drugs take longer, costing at least $1 billion to develop a new drug from scratch. The cycle of 10 to 20 years is often longer than that for new biological drugs.

Region Overview:

From 2022-2027, North America is estimated to witness robust growth prospects

Company Overview:

HitGen is one of the major players operating in the DNA-Encoded Library market, holding a share of 11.47% in 2021.

HitGen Inc

HitGen is a biotech company with headquarters and the main research facility based in Chengdu, China and a subsidiary in the USA. HitGen has established a platform for small molecule drug discovery and research centered on the design, synthesis and screening of DNA-encoded chemical libraries (DELs).

X-CHEM

X-Chem is a biotechnology company that enables customers to screen billions of compounds for targets through a breakthrough DNA-encoded library (DEL) screening platform. X-Chem experts invented DEL-driven drug discovery and will help customers take advantage of it.

Segmentation Overview:

Among different product types, Screening service / Hit identification segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Pharmaceutical and Biotech Companies segment occupied the biggest share from 2017 to 2022.

Key Companies in the global DNA-Encoded Library market covered in Chapter 3:

X-Chem
Novartis
Nurix Therapeutics
Vipergen
Philochem
Dice
HitGen
DyNAbind
HotSpot Therapeutics
Amgen
Merck KGaA
GSK
ComInnex

In Chapter 4 and Chapter 14.2, on the basis of types, the DNA-Encoded Library market from 2018 to 2029 is primarily split into:

Screening service / Hit identification
Development and DNA-encoded Library Service Kits
Hit optimization / Validation
Custom library design / Synthesis
In-house Drug
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the DNA-Encoded Library market from 2018 to 2029 covers:

Pharmaceutical and Biotech Companies
Research Institutes
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)